Related Experiment Video
Updated: Jan 29, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1
Satoshi Ikeda1, Keigo Araki1, Mai Kitagawa1
1Department of Thoracic Oncology, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan.
Cemiplimab, a stable anti-PD-1 antibody, shows promise for metastatic non-small cell lung cancer (NSCLC), especially in squamous histology with high PD-L1 expression.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- First-line treatment for metastatic non-small cell lung cancer (NSCLC) without driver mutations is evolving.
- Pembrolizumab-based regimens currently dominate the treatment landscape.
- Cemiplimab offers unique molecular characteristics as a novel anti-PD-1 antibody.
Purpose of the Study:
- To review the molecular features of cemiplimab.
- To define cemiplimab's optimal positioning in NSCLC treatment.
- To highlight its efficacy in specific patient populations.
Main Methods:
- Review of cemiplimab's structural advantages, including hinge-region mutation and PD-1 interaction.
- Analysis of data from the EMPOWER-Lung clinical trial program.
- Examination of efficacy in squamous NSCLC and PD-L1 expression subgroups.
Main Results:
- Cemiplimab's engineered stability minimizes anti-drug antibody (ADA) risks.
- Unique PD-1 interaction may enhance binding efficacy.
- Demonstrated survival benefits in ultra-high PD-L1 expression (TPS ≥90%) subgroup.
- Consistent efficacy in squamous NSCLC, both as monotherapy and combination therapy.
Conclusions:
- Cemiplimab shows significant promise in specific NSCLC populations.
- Its structural stability and reduced immunogenicity are key advantages.
- Establishes a therapeutic niche for squamous NSCLC with ultra-high PD-L1 expression.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
Ecological Niches
Stem Cell Niche
Other Unique Bacteria
Second Uniqueness Theorem
In contrast, consider that the electric field is non-unique and apply Gauss's law in divergence form in the region between the conductors and the integral form to the surface...
Cell Specific Gene Expression
Multipotency and Niche of Bulge Stem Cell